Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

Current Medical Research and Opinion

Volumn 27, Issue 5, 2011, Pages 951-960

  Villegas, A ^a   Arrizabalaga, B ^b   Fernandez Lago C ^c   Castro, M ^d   Mayans, J R ^e   Gonzalez Porras J R ^f   Duarte, R F ^g   Remacha, A F ^h   Luno E ⁱ   Gasquet, J A ^j  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d UNIVERSITY OF VIGO   (Spain)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g HOSPITAL DURAN I REYNALS   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^j Amgen SA   (Spain)

more..

Author keywords

Anemia; Darbepoetin alfa; Erythroid response; Fatigue; Myelodysplastic syndromes

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FATALITY; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; IRON DEFICIENCY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREDICTOR VARIABLE; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADULT; AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK FACTORS;

EID: 79954506128     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.561834     Document Type: Article

References (45)

1. Malcovati L, Nimer SD. Myelodysplastic syndromes: diagnosis and staging. Cancer Control 2008;15(Suppl.):4-13.
2. Jadersten M, Hellstrom-Lindberg E. Myelodysplastic syndromes: biology and treatment. J Intern Med 2009;265:307-28.
3. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-8. (Pubitemid 40204666)
4. Kouides PA, Bennett JM. Understanding the myelodysplastic syndromes. Oncologist 1997;2:389-401. (Pubitemid 28028594)
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99. (Pubitemid 12073508)
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
7. Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues: International Agency for Research on Cancer (IARC), 2008.
8. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88. (Pubitemid 27132124)
9. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10. (Pubitemid 47315575)
10. Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol Oncol 2001;19:19-30. (Pubitemid 32267844)
11. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26:132-49.
12. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991; 78:1658-63.
13. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998;103:1070-4.
14. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term followup of 71 patients. Blood 1998;92:68-75. (Pubitemid 28303177)
15. Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006;133:513-19.
16. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204-9.
17. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76.
18. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20. (Pubitemid 34993871)
19. Hedenus M, Hansen S, Taylor K, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86. (Pubitemid 35176501)
20. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34. (Pubitemid 37297759)
21. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(Suppl. 1):3-10. (Pubitemid 32453429)
22. Sekeres MA, Fu AZ, Maciejewski JP, et al. A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Cancer 2007;109:1125-32. (Pubitemid 46435391)
23. Rose EH, Abels RI, Nelson RA, et al. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995;89:831-7.
24. Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574-82.
25. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99:344-51. (Pubitemid 27497565)
26. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-4.
27. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag 2002;24:547-61. (Pubitemid 36120443)
28. Stasi R, Pagano A, Terzoli E, et al. Recombinant human granulocytemacrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. Br J Haematol 1999;105:141-8. (Pubitemid 29197156)
29. Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colonystimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87:4076-81. (Pubitemid 26152251)
30. Koury MJ, Bondurant MC. The molecular mechanism of erythropoietin action. Eur J Biochem 1992;210:649-63. (Pubitemid 23015763)
31. Backx B, Broeders L, Hoefsloot LH, et al. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand. Leukemia 1996;10:466-72. (Pubitemid 26128786)
32. Hoefsloot LH, Van Amelsvoort MP, Broeders LC, et al. Erythropoietin- induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997;89:1690-700. (Pubitemid 27097463)
33. Rigolin GM, Porta MD, Bigoni R, et al. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsastained bone marrow samples. Br J Haematol 2002;119:652-9. (Pubitemid 35366204)
34. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
35. Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002;118:174-80. (Pubitemid 34779534)
36. Remacha AF, Arrizabalaga B, Villegas A, et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 1999;84:1058-64. (Pubitemid 30016577)
37. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104:321-7. (Pubitemid 38900010)
38. Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000;109:367-75. (Pubitemid 30350720)
39. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin \+ granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037-46. (Pubitemid 36411563)
40. Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008;142:379-93. (Pubitemid 351962168)
41. Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005;16:1921-7. (Pubitemid 41724281)
42. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122:394-403. (Pubitemid 36951623)
43. Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesisstimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007;12:1264-73. (Pubitemid 350106357)
44. Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87:527-36.
45. Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009;115:706-15